The Nuclear Medicine Institute at Rambam Healthcare Campus provides the full range of nuclear medical imaging services for diagnostic and prognostic purposes, and to monitor the response to various treatment strategies. In addition the institute also provides treatment using radioactive materials for medical conditions such as diseases of the thyroid and bone, and lymphoma.

Unique to Rambam are the institute's hybrid imaging systems, which offer sophisticated diagnostic and treatment capabilities. For oncology patients, the institute is the single center in Northern Israel offering PET/CT studies, which enable development of accurate and focused treatment strategies; surgical approaches and radiation fields can be planned more precisely, and chemotherapy can be tailored according to the imaging results of the patient.

PET/CT is also applied to new clinical indications, developed and explored in a pioneering approach at Rambam for diagnosis and assessment of infectious processes, particularly in diabetic patients. In the field of cardiology, the novel SPECT/64-slice CT device (unique to Rambam, and one of very few systems worldwide) can determine prognosis of patients after acute myocardial infarction, evaluate risk prior to surgery, and define medical or interventional therapeutic strategies in patients with localized or diffuse coronary artery disease. 

Nuclear medicine is also successfully applied in Sports Medicine, for evaluating skeletal changes and bone pain, for guiding treatment in a wide variety of endocrine diseases, in assessment of a variety of disease processes in children, and in many other clinical fields.

The PET/CT and SPECT/CT imaging technologies developed in collaboration with physicians at Rambam's Nuclear Medicine Institute, whose expertise in the clinical use of these systems is unsurpassed.

The institute is involved in a wide range of clinical and research activities, in the context of the Rambam Healthcare Campus, in collaboration with the Technion, and in international joint projects with institutions such as the Harvard Joint Program in Nuclear Medicine, Johns Hopkins and Vanderbilt Universities.